Associated Papers
RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236.
Pfeil AJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236.
Pfeil AJ et al.
Biorxiv : the Preprint Server for Biology, 2025
The RRAS2 pathogenic variant (c.67G>T; p. Gly23Cys) produces Noonan syndrome with embryonal rhabdomyosarcoma.
Zeng L et al.
Molecular Genetics & Genomic Medicine, 2024
Functional analysis of RRAS2 pathogenic variants with a Noonan-like phenotype.
Iida T et al.
Frontiers in Genetics, 2024
38601074 (PubMed )
Supplement: Table3.XLSX › p.Gly23Val
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
33226070 (PubMed )
Supplement: btaa972_supplementary_data.zip › RAS_Manuscript_RMarkdown.tar.gz › RAS_Manuscript1.Revised › RAS_Variants_Scores.xlsx › Sheet1
Select a paper to view details